Yükleniyor... / Loading...
This observational study follows patients in China with unresectable advanced non-small cell lung cancer that cannot be treated with surgery. It includes patients with stage IIIB/IIIC/IV disease who are receiving or will receive standard first-line treatment. It is a study without an assigned phase and is active but not currently recruiting.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: Cohort 1: * Participants who have diagnosed with unresectable stage IIIB/IIIC/IV NSCLC * Participants who have been diagnosed six months before the start of the study were required to have two complete tumor assessments within at least 6 months intervals after the diagnosis * Participants who were newly diagnosed within six months before the start of the study were required to have complete baseline information (see section 6.4.1) * Participants who have received standard first-line treatment defined by guideline CSCO (https://www.csco.org.cn/cn/index.aspx) and NCCN (https://www.nccn.org/) Cohort 2: * Participants who are newly diagnosed with unresectable Stage IIIB/IIIC/IV NSCLC after the start of the study * Participants who are able to be followed up by the participating site * Participants planned to receive first line anti-cancer treatment targeting unresectable stage IIIB/IIIC/IV NSCLC in the study site after study initiation Exclusion Criteria: * Participants who have received prior systematic treatment for unresectable Stage IIIB/IIIC/IV NSCLC * Participants who have participated in any anti-cancer, regimen-specified clinical study of first-line treatment for unresectable Stage IIIB/IIIC/IV NSCLC